Alto Neuroscience Announces $120 Million Private Placement Financing [Yahoo! Finance]
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Yahoo! Finance
– Financing led by Commodore Capital with participation from new and existing biotech focused investors – – Alto expects to use the proceeds of the financing to support the development of ALTO-207 in Treatment Resistant Depression through a planned Phase 3 study and to a potential NDA submission – MOUNTAIN VIEW, Calif., March 16, 2026 BUSINESS WIRE )--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately $120 million, before deducting offering expenses. The financing is being led by Commodore Capital, with participation from new and existing institutional investors, including Dellora Investments, Driehaus Capital Management, Perceptive Advisors
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- Alto Neuroscience (ANRO) had its price target raised by Robert W. Baird from $22.00 to $41.00. They now have an "outperform" rating on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its price target raised by Wedbush from $13.00 to $22.00. They now have a "neutral" rating on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Alto Neuroscience announces $120M private placement financing [Seeking Alpha]Seeking Alpha
ANRO
Earnings
- 3/16/26 - Miss
ANRO
Sec Filings
- 3/16/26 - Form 8-K
- 3/16/26 - Form S-8
- 3/16/26 - Form 10-K
- ANRO's page on the SEC website